New Pancreatic Cancer Drug Could Be a Lifesaver for Many Patients
The oral pill nearly doubled median overall survival in previously treated patients and is the first RAS-targeted therapy approved for this cancer.
8 Articles
8 Articles
The American Food and Drug Administration (FDA) has approved the new drug daraxonrasib, which is also sold under the name Rasonque, for treating an adult patient with metastatic pancreatic adenocarcin. The decision was announced as of August 26, 2026. Therapy is intended for patients who have received only systemic treatment, such as for choirs who are not suitable for combined systemic therapy. The drug is taken daily under the format per table…
StockWatch: Revolution Shares Stay Flat Despite Historic FDA Approval of Oral Pancreatic Cancer Therapy
In April, Revolution shares rocketed 54% after the company announced dazzling data from its Phase III RASolute 302 trial (NCT06625320) evaluating Rasonque in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) who had been previously treated. In the overall intent-to-treat population of the Phase III RASolute 302 trial (NCT06625320), daraxonrasib showed a median overall survival (OS) of 13.2 months, nearly double the 6.7 months demo…
Coverage Details
Bias Distribution
- 75% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
